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Abstract 2-Oxoglutarate or α-ketoglutarate (αKG) is a
substrate of HIF prolyl hydroxylases 1–3 that decrease
cellular levels of the hypoxia-inducible factor 1α (HIF-1α)
in the presence of oxygen. αKG analogs are applied to
stabilize HIF-1α even in the presence of oxygen and thus
provide a novel therapeutic option in treating kidney dis-
eases. In the kidneys, the organic anion transporters 1 and 3
(OAT1 and OAT3, respectively) in cooperation with the
sodium-dependent dicarboxylate transporter 3 (NaDC3)
and the OAT4 might be responsible for the uptake of αKG
analogs into and the efflux out of the tubular cells. Using the
radiolabelled substrates p-aminohippurate (PAH, OAT1),
estrone-3-sulfate (ES; OAT3, OAT4), and succinate
(NaDC3), N-oxalylglycine (NOG), dimethyloxalyl glycine
(DMOG), 2,4-diethylpyridine dicarboxylate (2,4-DPD), and
pyridine-2,4-dicarboxylic acid (PDCA) were tested in cis-
inhibition and trans-stimulation experiments. None of these
αKG analogs interacted with NaDC3. 2,4-DPD and PDCA
inhibited ES uptake byOAT3moderately. NOG, 2,4-DPD and
PDCA, but not DMOG, inhibited PAH uptake by OAT1
significantly. trans-Stimulation experiments and experiments
demonstrating stabilization of HIF-1α revealed that NOG and
PDCA, but not 2,4-DPD, are translocated by OAT1. All
compounds trans-stimulated ES uptake by OAT4, but only
PDCA stabilized HIF-1α. The data suggest that OAT1 is
involved in the uptake of NOG and PDCA across the baso-
lateral membrane of proximal tubule cells, whereas OAT4
may release these compounds into the primary urine.
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Introduction
Hypoxia-inducible factors (HIFs) orchestrate the genomic
response to hypoxia in a variety of cells. Numerous HIF target
genes have been identified, their products being involved in
central cellular mechanisms such as glycolysis, angiogenesis,
matrix deposition, and erythropoiesis [for review, see 8, 10,
23]. HIFs areα, ß heterodimers.Whereas the ß-subunit of HIF
is constitutively present, HIF-α-subunits [23, 25] are regulat-
ed by oxygen levels. Under normoxic conditions, HIF-1α is
hydroxylated at prolines 564 and 402 by three functional HIF
prolyl hydroxylase domains (PHDs [7, 14, 15]). Hydroxyl-
ation of these prolines mediates recognition of HIF by the von
Hippel–Lindau tumor suppressor protein as part of an E3
ubiquitin ligase, resulting in ubiquitylation of HIF-1α and its
degradation in the proteasome [19]. Moreover, the C-terminus
of the HIF-1α subunit is hydroxylated by the factor inhibiting
HIF (FIH1) in the presence of oxygen which blocks interac-
tion of HIF with the transcriptional coactivator p300 and may
serve as a final transcriptional control of HIF target genes
under normoxic conditions [18]. In contrast, under hypoxia,
the dioxygen-dependent hydroxylases are not active, and the
unmodified HIF-1α proteins become transcriptionally active
by heterodimerization with HIF-ß.
PHDs belong to the Fe(II) and 2-oxoglutarate (α-
ketoglutarate (αKG))-dependent dioxygenase family, which
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use oxygen and αKG as substrates and contain Fe2+ in their
catalytic center. αKG is used as an electron donor and is
consequently oxidized to succinate which, in turn, is a
physiological inhibitor of the PHDs. Analogs of αKG and
citric acid cycle intermediates were developed as potential
drugs to inhibit the PHDs and thereby allow the function of
HIF even in the presence of oxygen in cell culture [17, 20]
as well as in animal studies of acute renal failure [3] and
chronic kidney disease [22, 26].
In humans, acute hypoxic kidney injury is associated
with extensive proximal tubular necrosis with preservation
of glomeruli and distal nephron segments [12], indicating
that proximal tubular cells are particularly vulnerable to
oxygen deprivation because of their high metabolic activity.
An increase in HIF or a decrease in PHD activity would be a
therapeutic option to attenuate or even prevent injury of
proximal tubule cells under hypoxic conditions. In most in
vitro studies, dimethyloxalyl glycine (DMOG) was applied
which competes for binding with αKG to the catalytic site
of the PHDs, thereby protecting the cells from undergoing
apoptosis. Besides DMOG, N-oxalylglycine (NOG),
pyridine-2,4-dicarboxylic acid (PDCA), and 2,4-diethylpyr-
idine dicarboxylate (2,4-DPD) are available as PHD inhib-
itors (Fig. 1). NOG and PDCA are negatively charged and
may not be able to enter cells by simple diffusion.
If, however, proximal tubule cells possess transporters
accepting negatively charged hydrophilic αKG analogs as
substrates, these compounds could offer a promising thera-
peutic approach to selectively reduce kidney injury. The
basolateral membrane of proximal tubule cells is equipped
with an array of transporters; among them, the organic anion
transporters (OATs [for review 1, 2, 5]) are characterized by
broad substrate specificities. Substrates for OATs are strik-
ingly chemically diverse, and identified classes include anti-
neoplastics, antibiotics, antihypertensives, non-steroidal
anti-inflammatory drugs, biogenic amine metabolites, ste-
roid hormones and their metabolites, and several toxins.
Two OATs, OAT1 and OAT3, are located at the basolateral
membrane [21] and one, OAT4, at the luminal membrane of
proximal tubule cells [6]. All these transporters operate as
anion exchangers, i.e., they couple the uptake of an organic
anion into the cell to the release of another organic anion
from the cell [for review 1, 2, 5]. OAT1 and OAT3 utilize
the existing intracellular > extracellular gradient for αKG to
drive uphill uptake of organic anions against the inside
negative membrane potential. This αKG gradient is estab-
lished by the sodium-dependent dicarboxylate transporter 3
(NaDC3). Whereas OAT1 and OAT3 accept dicarboxylates
from the extracellular as well as from the intracellular
side, OAT4 appears to be an asymmetric transporter
by accepting dicarboxylates or compounds with
dicarboxylate-like structures only from the intracellular
side of the transporter [11].
Since the above-mentioned transporters interact with
dicarboxylates, we hypothesized that, in proximal tubule
cells, PHD-inhibiting αKG analogs are taken up from the
interstitial space across the basolateral membrane either by
OAT1, OAT3, or NaDC3, and are released into the urine by
OAT4. This hypothesis is based on our finding that αKG,
succinate, glutarate, and fumarate are high-affinity sub-
strates for these transporters [16], and some of these PHD




Human OAT1 and OAT3 (GeneBank accession numbers:
AF057039 and AF097491) were obtained from Resource
Center for Genome Research (Berlin, Germany). Human
OAT4 (GeneBank accession number: AL514126) was from
Invitrogen (Groningen, The Netherlands). Human NaDC3
possesses the GeneBank accession no. AF154121. The
stably transfected human epithelial kidney cells T-REX™-
HEK293-OAT1, -HEK293-OAT3, -HEK293-OAT4,
and -HEK293-hNaDC3 were established using the
Flp-In™ expression system (Invitrogen) according to the
manufacturer's instructions. Stably transfected HEK293
cells were grown in flasks coated with 0.1 mg/ml poly-L-
lysine in high-glucose DMEM medium (Invitrogen) supple-
mented with 10 % fetal calf serum (EU approved origin,
Gibco/Invitrogen), 1 % penicillin/streptomycin, and blasti-
cidine (5 mg/l; all antibiotics from Sigma, Taufkirchen,
Germany). Control cells were transfected with the vector
alone. Cultures were maintained in humidified atmosphere
that contained 5 % CO2 at 37 °C.
Solutions
A standard mammalian Ringer solution (MRi) was used for
the uptake experiments. MRi contained (in millimolars):
130 NaCl, 4 KCl, 1 CaCl2, 1 MgSO4, 1 NaH2PO4, 20
HEPES, and 18 glucose at pH 7.4. Sodium-free conditions
were obtained by equimolar substitution of NaCl by tetrae-
thylammonium chloride (TEACl). Test substances for cis-
inhibiton or trans-stimulation experiments were succinate,
glutarate, α-ketoglutarate (αKG), N-oxalylglycine (NOG),
2,4-diethylpyridine dicarboxylate (2,4-DPD), dimethylox-
alyl glycine (DMOG), and pyridine-2,4-dicarboxylic acid
(PDCA). Chemicals of analytical grade for the uptake
experiments and also for the immunoblots (see below) were
either from Sigma or from Applichem (Darmstadt,
Germany). The αKG analogs were obtained from Alexis
(Alexis/Axxora, Lörrach, Germany).
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Tracer uptake experiments
HEK293-OAT1-, -OAT3-, -OAT4-, -NaDC3-, and vector-
transfected cells were harvested and plated into 24-well plastic
dishes (Sarstedt, Nürmbrecht, Germany) at a density of 2×105
cells/well. For protein quantification, a separate plate was
used, seeded with the same cell density per well. The protein
amount was determined in parallel from six wells for each cell
line in nine independent experiments using a photometric
method described by Bradford [4]. Transport assays were
performed 72 h after seeding the cells in MRi. At the end of
culture, cells were washed twice with 0.5 ml MRi and incu-
bated for 5 min in MRi that contained 1.2 μM [3H]p-amino-
hippuric acid (3H-PAH, 4.35 Ci/mmol; Perkin Elmer,
Rodgau, Germany) for OAT1-, 10 or 20 nM [3H]estrone
sulfate (3H-ES, 57.3 Ci/mmol; Perkin Elmer) for OAT3- and
OAT4-, or 1 μM [14C]succinate (14C-succinate, 58 mCi/
mmol; Perkin Elmer) for NaDC3-transfected HEK293 cells.
IC50 values for OAT1 were performed with 10 μM total PAH.
Uptake was terminated by removal of the radioactive medium
and immediate 3 1 ml washes with ice-cold MRi. The cells
were dissolved in 0.5 ml 1 N NaOH by gently shaking for
120 min followed by neutralization with 0.5 ml 1 N HCl. The
3H-or 14C-content was determined by liquid scintillation
counting (Tricarb 2900TR, Perkin Elmer).
For trans-stimulation experiments, either OAT1- or
OAT4-transfected HEK293 cells, were preincubated for
2 h in MRi containing either 100 μM DMOG, NOG, 2,
4-DPD, or PDCA. Thereafter, the respective cell line was
washed two times in MRi and the uptake of radiolabelled
PAH (OAT1) or ES (OAT4), respectively, was performed as
described above.
Immunoblots
Anti-HIF-1α immunoblots were performed using whole cell
extracts taken from OAT1-, OAT4-, or vector-transfected
HEK293 cells grown on 10-cm dishes (approx. 3×106
cells/dish) to subconfluency. Cells were incubated for 4 h
in high glucose DMEM medium (Invitrogen) supplemented
with 10 % fetal calf serum (EU approved origin, GIBCO/
Invitrogen) containing in addition either 100 μM dipyridil
(DP), 1 mM DMOG, 500 μM NOG, 500 μM 2,4-DPD, or
100 μM PDCA in the presence and absence of 1 mM
probenecid. Afterwards, cells were lysed in 6.65 M urea,
10 % glycerol, 1 % sodium dodecylsulfate 10 mM TRIS/
HCl, 5 mM dithiotreitol, and protease inhibitor Complete®
(Roche Diagnostics, Mannheim, Germany). Protein (100 μg)
was separated on 10 % polyacrylamide gels, transferred onto
polyvinylidene difluoride membranes (BioRad, Munich,
Germany) and incubated with antibodies against HIF-1α and
ß-actin (1:2,000, Cayman Chemical, Ann Arbor, MI). Subse-
quently, blots were exposed to horseradish peroxidase-
conjugated secondary antibodies (Dako, Hamburg, Germany),
and signals were visualized by chemiluminescence (Amersham
ECL-Plus, GE healthcare, Buckinghamshire, UK).
Statistics
Paired Student's t tests were used to show statistical signif-
icant differences for the inhibition of the uptake of either
PAH, ES, or succinate by the test substances. Statistical
significance was set at p<0.001. IC50 values for the inhibi-
tion of PAH uptake by NOG, 2,4-DPD, and PDCA were
































pyridine-2,4-dicarboxylic acid (PDCA) 2,4-diethylpyridine dicarboxylate (2,4-DPD)
Fig. 1 Chemical structures of
glutaric acid, α-ketoglutaric
acid, and αKG analogs. The
chemical structures were
constructed by the free version
of ChemSketch or by the data
sheet of the supplier
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Richmond, CA, USA). All uptake experiments were per-
formed at least in triplicate using cell cultures from consec-
utive cell culture passages. The immunoblot (Fig. 7) was
performed twice with identical results.
Results
Interactions of α-ketoglutarate (αKG) analogs with the hu-
man sodium-dependent dicarboxylate transporter 3
(NaDC3)
In three independent experiments, the 5-min uptake of succi-
nate was determined to 547.7±39.3 and 10.1±0.9 pmol/mg
protein in HEK293 cells stably transfected with NaDC3 or
vector, respectively. Succinate uptake was abolished when all
sodium was replaced by TEA (Fig. 2, sodium-free), demon-
strating that NaDC3 was functionally expressed in HEK293
cells (Fig. 2). Unlabelled succinate (100 μM) reduced uptake
of labelled succinate by 73.4±4.7 %. Whereas application of
theαKG analogs NOG and PDCA and the related compounds
DMOG and 2,4-DPD (each 100 μM) did not inhibit succinate
uptake (Fig. 2), the naturally occurring dicarboxylates gluta-
rate and αKG inhibited succinate uptake by 60.9±0.7 and
46.2±3.9 %, respectively.
Influence ofαKG analogs on OAT3-transfected HEK293 cells
Functional expression of OAT3 was tested by demonstrating
inhibition of ES uptake by unlabelled ES and by probenecid
(Fig. 3). At a concentration of 100 μM, 2,4-DPD and PDCA
inhibited ES uptake by 31.3±8.3 % and 29.7±5.7 %,
respectively. NOG and DMOG exhibited no effect on ES
uptake. In vector-transfected cells, ES uptake was similar
under all experimental conditions and less than 15 % of the
uptake observed in OAT3-transfected HEK293 cells.
Influence ofαKG analogs on OAT1-transfected HEK293 cells
The 5 min uptake of PAH, the prototypical substrate of
OAT1, was 91.1±11.7 and 3.1±0.4 pmol/mg protein in
OAT1- and vector-transfected cells, respectively. Unlabelled
PAH and probenecid evoked a substantial inhibition on PAH
uptake, indicating successful transfection of the HEK293
cells with OAT1. From the four compounds tested, NOG,
2,4-DPD, and PDCA at a concentration of 100-μM
inhibited uptake of PAH significantly in OAT1-transfected
HEK293 cells. DMOG was not effective (Fig. 4A). To
investigate whether NOG, 2,4-DPD, and PDCA are not only
inhibitors of OAT1-mediated PAH uptake but are also sub-
strates of OAT1, trans-stimulation experiments were per-
formed. To this end, OAT1-transfected HEK293 cells were
preloaded for 2 h with 2,4-DPD, DMOG, PDCA, and NOG
(Fig. 4B). Uptake of PAH was significantly trans-stimulated
upon preloading the cells with NOG, DMOG, and PDCA,
but not with 2,4-DPD. To further elucidate, which of the
three compounds has the highest potency in inhibiting PAH
uptake, IC50 values were determined. NOG (Fig. 5A), 2,
4-DPD (Fig. 5B), and PDCA (Fig. 5C) showed inhibition of
PAH uptake with IC50 values of 79.6±10.2, 60.9±3.0, and
19.1±6.1 μM, respectively.
Substrate specificity of OAT4-transfected HEK293 cells
OAT4 has recently been identified as an asymmetric trans-
porter, accepting dicarboxylates only from the cytosol.
succinate uptake (%)


















Fig. 2 Effect of several αKG analogs on succinate uptake in NaDC3-
and vector-transfected HEK293 cells. The 5-min succinate uptake was
measured in the absence and presence of succinate, αKG, and various
αKG analogs (each 0.1 mM). The uptake in the presence of a putative
substrate was calculated as the percentage of the uptake measured in
the absence of this compound (none) which was set to 100 %. Values
are mean ± SEM of 3–4 independent experiments; asterisk p<0.001
versus “none”
ES uptake (%)














Fig. 3 Effect of several αKG analogs on ES uptake in OAT3- and
vector-transfected HEK293 cells. The 5-min ES uptake was measured
in the absence (none) and presence of various compounds. The con-
centration of the inhibitor used was 100 μM. Values are mean ± SEM
of 3–4 independent experiments; asterisk p<0.001 versus “none”
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Successful transfection with OAT4 was proven by up-
take of ES which was 199.6±14.9 in OAT4-transfected
and 25.3±3.2 fmol/mg protein in vector-transfected
control cells. ES uptake was inhibited by unlabelled
ES and probenecid (Fig. 6A). While application of the
αKG analogs (100 μM) on OAT4-transfected HEK293
cells (Fig. 6A) showed no effect on ES uptake, pre-
loading the cells with 2,4-DPD, DMOG, NOG, and
PDCA for 2 h (Fig. 6B) resulted in significantly in-
creased uptake of ES (trans-stimulation). As an internal
control, glutarate was used in these experiments































Fig. 4 Effect of several αKG analogs on PAH uptake in OAT1-
and vector-transfected HEK293 cells. a Cis-inhibition of PAH
uptake by αKG analogs. The 5-min PAH uptake was measured
in the absence (none) and presence of various compounds. The
concentration of the inhibitor used was 0.1 mM. b Trans-stimu-
lation of PAH uptake in OAT1-transfected HEK293 cells by
NOG, DMOG, and PDCA, but not by 2,4-DPD. Cells were
preloaded for 2 h in the indicated compounds. Immediately after
washing out of the indicated compound, 5-min PAH uptake was
measured. The uptake in the presence of any putative substrate
was set to 100 %, and the uptake of the respective αKG analog was set in
relation. a, b show the summary of three independent experiments where
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Fig. 5 Determination of IC50 for the inhibition of OAT1-mediated
PAH uptake by NOG (a), 2,4-DPD (b), and PDCA (c). Plots were
obtained by using 10 μM total PAH and increasing NOG (a), 2,4-DPD
(b), or PDCA (c) concentrations up to 500 μM at an uptake time of
5 min. Each plot shows mean values of three independent experiments
Pflugers Arch - Eur J Physiol (2012) 464:367–374 371
Stabilization of HIF-1α in OAT1- and OAT4-transfected
HEK293 cells
Finally, we tested for HIF-1α stabilization in HEK293 cells
stably transfected with OAT1 or vector alone after treatment
with PHD inhibitors in the absence and presence of proben-
ecid (Fig. 7). The Fe2+ chelator dipyridyl (DP) was used as a
freely permeable positive control. With the exception of 2,
4-DPD, application of all PHD inhibitors induced HIF-1α in
OAT1-, but not in vector-transfected cells. Stabilization of
HIF-1α was prevented by the simultaneous application of
probenecid (1 mM) with either NOG or PDCA (0.5 or
0.1 mM, respectively), indicating that NOG and PDCAwere
translocated by OAT1. In OAT4-transfected cells, a marginal
stabilization of HIF-1α was observed by PDCA, and this
effect was abolished by probenecid. DMOG stabilized HIF-
1α in OAT1- as well as in OAT4- and in vector-transfected
cells, and this effect was partially abolished by probenecid.
Discussion
Stabilization of HIF by carbon monoxide or available PHD
inhibitors has been shown to have significant beneficial
effects in models of acute ischemic and toxic kidney injury
[3, 9, 12, 13, 22, 26, 27]. On the other hand, hypoxia has
been shown to promote interstitial fibrosis and support
epithelial-to-mesenchymal transition which has been pro-
posed to be a major pathophysiological mechanism leading
to progressive chronic kidney disease [10]. Whether PHD
inhibitors structurally related to αKG show also unwanted
side effects can only be elucidated in clinical studies. Our
experiments, however, demonstrated interaction of PDCA,
NOG, and 2,4-DPD with OAT1. The IC50 values for inhi-
bition of PAH uptake by these compounds we obtained
varied between 19 and 80 μM. These values are in agree-
ment with recently reported IC50 or Ki values for NOG and
PDCA against human αKG dioxygenases which are in the






























Fig. 6 Effect of several αKG analogs on ES uptake in OAT4- and
vector-transfected HEK293 cells. a cis-inhibition and b trans-stimula-
tion experiments. The 5-min uptake of ES uptake was measured in the
absence and presence of various PHD inhibitors and related com-
pounds (100 μM) (a). Cells were preloaded for 2 h in the indicated
compounds (500 μM in MRi) (b). Immediately after a wash-out of the
indicated compound, 5-min ES uptake was measured. Under both
conditions, the uptake in the absence of any putative substrate was
set to 100 % and the inhibition (a) or stimulation (b) of uptake was set
into relation. Each plot shows the summary of three to four indepen-



























































Fig. 7 Stabilization of HIF-1α in OAT1- and OAT4-tansfected
HEK293 cells. HIF-1α immunoblot of OAT1- (top), OAT4- (middle),
and vector-transfected (base) HEK293 cells after treatment with the
chemical HIF inductor dipyridil (DP) as a positive control or the PHD
inhibitors DMOG (1 mM), NOG (0.5 mM), 2,4-DPD (0.5 mM), and
PDCA (0.1 mM) in the absence and presence of probenecid (1 mM).
The concentrations of NOG, 2,4-DPD, and PDCAwere chosen three to
five times above the IC50 as determined in OAT1-transfected HEK293
cells. Proteins (0.1 mg) were transferred onto polyvinylidine difluoride
membranes and incubated with the antibodies. Blots were performed in
duplicate, and both trials showed comparable results
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Data on the uptake of αKG analogs across the plasma
membrane of target cells have not been available so far.
Whereas uncharged compounds such as DMOG and 2,
4-DPDmay cross cell membranes by simple diffusion, uptake
of the dianionic NOG and PDCA should require interaction
with transporters accepting dicarboxylates. To this end, the
impact of NOG, DMOG, 2,4-DPD, and PDCA on the human
organic anion transporters OAT1, 3, and 4 and on the human
sodium-dependent dicarboxylate transporter (NaDC3) was
tested. These transporters are expressed either in the baso-
lateral (OAT1, OAT3, NaDC3) or the luminal membrane
(OAT4) of proximal tubule cells. To demonstrate an interac-
tion of the PHD inhibitors with the transporters, concentra-
tions similar to those applied in other cell culture studies
(0.1–1 mM [17, 20]) were applied. These concentrations were
sufficient to stabilize HIF in vitro.
NaDC3 was not sensitive towards all tested αKG ana-
logs, and only the physiological substrates, glutarate, and
αKG inhibited succinate uptake. Hence, it is likely that
NaDC3 is not involved in the Na+-dependent uptake of
αKG analogs into proximal tubular cells. ES uptake in
OAT3-transfected HEK293 cells was not (NOG, DMOG)
or weakly (2,4-DPD; PDCA) affected, suggesting a limited,
if any, role in the uptake of αKG analogs.
DMOG did not inhibit the uptake of PAH in OAT1-
transfected HEK293 cells, indicating that the two methyl
groups and the absence of negative charges avoid transport
by OAT1. Hydroxylation of HIF can be inhibited by DMOG
[for review, see 22, 26], and our own results are shown in
Fig. 7. It seems that DMOG permeates the cell membrane
not only by simple diffusion but also by a probenecid-
inhibitable mechanism, as revealed by comparison of the
staining in the immunoblots by DMOG in the absence and
presence of probenecid (Fig. 7, 1st, 5th row). The nature of
the underlying endogenous transporter present in OAT1-
and vector-transfected HEK293 cells is unknown. The sec-
ond uncharged compound tested, 2,4-DPD, inhibited PAH
uptake by OAT1 with an IC50 of approx. 60 μM. Since 2,4-
DPD was unable to trans-stimulate PAH uptake and also no
stabilization of HIF-1α was observed, we suggest that this
compound inhibits OAT1 but itself does not enter cells by
diffusion nor by OAT1-mediated transport.
The divalent anions, NOG and PDCA, are substrates of
OAT1 as they not only decreased PAH uptake in cis-inhibi-
tion experiments but also increased it in trans-stimulation
experiments. These data do not prove but strongly suggest
that OAT1 translocate NOG and PDCA across cell mem-
branes. An indication that NOG and PDCA are substrates of
OAT1 is provided by the stabilization of HIF-1α by NOG
and PDCA in OAT1- but not in vector-transfected cells.
That these compounds use OAT1 for translocation is sup-
ported by the observation that stabilization of HIF-1α is
prevented by probenecid, an inhibitor of OAT1.
With respect to OAT4, unexpected results were obtained.
Whereas in cis-inhibition experiments αKG analogs were
not effective on OAT4-transfected HEK293 cells, all com-
pounds were found to trans-stimulate ES uptake. From
these compounds, only PDCA stabilized HIF-1α. It appears
that PDCA has a weak affinity to OAT4 which was
not detected in cis-inhibition experiments. During the
4-h incubation, however, sufficient PDCA entered the
OAT4-transfected HEK293 cells to stabilize HIF-1α. The
specificity of this effect was evaluated by the simultaneous
application of PDCA and probenecid which prevented sta-
bilization of HIF-1α in these cells.
Preloading cells with NOG and 2,4-DPD afforded a
trans-stimulation of OAT4-mediated ES uptake, but no sta-
bilization of HIF-1α. Possibly, OAT4 mainly acts as an
efflux transporter keeping intracellular concentrations of
NOG and 2,4-DPD too low for a measurable HIF-1α
stabilization.
In summary, our data indicate that NOG and PDCA may
be taken up from the blood into the proximal tubule cells by
OAT1 and released into the primary urine by OAT4.
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